LPL Financial’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.64M | Buy |
8,211
+3,938
| +92% | +$779K | ﹤0.01% | 3695 |
|
|
2025
Q4 | $808K | Buy |
4,273
+866
| +25% | +$166K | ﹤0.01% | 4282 |
|
|
2025
Q3 | $604K | Sell |
3,407
-1,759
| -34% | -$261K | ﹤0.01% | 4470 |
|
|
2025
Q2 | $587K | Buy |
+5,166
| New | +$552K | ﹤0.01% | 4246 |
|
|
2024
Q4 | – | Sell |
-3,075
| Closed | -$308K | – | 5378 |
|
|
2024
Q3 | $308K | Buy |
3,075
+119
| +4% | +$12K | ﹤0.01% | 4413 |
|
|
2024
Q2 | $249K | Buy |
+2,956
| New | +$235K | ﹤0.01% | 4402 |
|
|
2022
Q4 | – | Sell |
-6,006
| Closed | -$323K | – | 4512 |
|
|
2022
Q3 | $323K | Buy |
6,006
+934
| +18% | +$54.9K | ﹤0.01% | 3523 |
|
|
2022
Q2 | $282K | Buy |
5,072
+568
| +13% | +$32.2K | ﹤0.01% | 3677 |
|
|
2022
Q1 | $316K | Sell |
4,504
-587
| -12% | -$42.6K | ﹤0.01% | 3538 |
|
|
2021
Q4 | $491K | Buy |
5,091
+229
| +5% | +$21.2K | ﹤0.01% | 3296 |
|
|
2021
Q3 | $423K | Buy |
4,862
+426
| +10% | +$32.9K | ﹤0.01% | 3371 |
|
|
2021
Q2 | $363K | Buy |
4,436
+151
| +4% | +$12.6K | ﹤0.01% | 3434 |
|
|
2021
Q1 | $407K | Buy |
+4,285
| New | +$405K | ﹤0.01% | 3204 |
|
|
2020
Q1 | – | Sell |
-3,092
| Closed | -$201K | – | 3340 |
|
|
2019
Q4 | $201K | Sell |
3,092
-411
| -12% | -$27.5K | ﹤0.01% | 3102 |
|
|
2019
Q3 | $217K | Buy |
+3,503
| New | +$220K | ﹤0.01% | 2928 |
|
|
2019
Q1 | – | Sell |
-3,921
| Closed | -$332K | – | 3223 |
|
|
2018
Q4 | $332K | Sell |
3,921
-9,224
| -70% | -$983K | ﹤0.01% | 2390 |
|
|
2018
Q3 | $2.25M | Buy |
13,145
+7,929
| +152% | +$1.2M | 0.01% | 1104 |
|
|
2018
Q2 | $674K | Buy |
+5,216
| New | +$582K | ﹤0.01% | 1941 |
|
|
2018
Q1 | – | Sell |
-6,537
| Closed | -$558K | – | 3224 |
|
|
2017
Q4 | $558K | Sell |
6,537
-255
| -4% | -$22.1K | ﹤0.01% | 1966 |
|
|
2017
Q3 | $577K | Buy |
6,792
+382
| +6% | +$30.2K | ﹤0.01% | 1840 |
|
|
2017
Q2 | $485K | Sell |
6,410
-2,273
| -26% | -$159K | ﹤0.01% | 1902 |
|
|
2017
Q1 | $572K | Buy |
8,683
+1,407
| +19% | +$92.6K | ﹤0.01% | 1684 |
|
|
2016
Q4 | $465K | Buy |
7,276
+1,149
| +19% | +$72.5K | ﹤0.01% | 1806 |
|
|
2016
Q3 | $384K | Sell |
6,127
-121
| -2% | -$8.88K | ﹤0.01% | 1937 |
|
|
2016
Q2 | $482K | Buy |
6,248
+2,359
| +61% | +$175K | ﹤0.01% | 1709 |
|
|
2016
Q1 | $269K | Buy |
+3,889
| New | +$236K | ﹤0.01% | 2597 |
|
|
2015
Q1 | – | Sell |
-26,036
| Closed | -$864K | – | 2833 |
|
|
2014
Q4 | $864K | Buy |
+26,036
| New | +$847K | ﹤0.01% | 1412 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
LPL Financial's LGND Position: Q1 2026 in Review
LPL Financial increased its Ligand Pharmaceuticals (LGND) stake by 92% in Q1 2026, buying an estimated $779K and bringing the position to 8,211 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3695.
LPL Financial first reported a position in LGND in Q4 2014 and has held it in 27 quarters since. The position peaked at $2.25M in Q3 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- LPL Financial held 8,211 shares of Ligand Pharmaceuticals worth $1.64M as of Q1 2026.
- LPL Financial bought 3,938 Ligand Pharmaceuticals shares in Q1 2026, an estimated $779K.
- Ligand Pharmaceuticals made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #3695 holding.
- LPL Financial first reported a position in Ligand Pharmaceuticals in Q4 2014 and has held it in 27 quarters since.
- LPL Financial's Ligand Pharmaceuticals position peaked at $2.25M in Q3 2018.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.